Notice: This company has been marked as potentially delisted and may not be actively trading. Cerevel Therapeutics (CERE) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends Get the Latest News and Ratings for CERE and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cerevel Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up CERE Analyst Ratings Over TimeTypeCurrent Forecast12/22/23 to 12/21/241 Month Ago11/22/23 to 11/21/243 Months Ago9/23/23 to 9/22/241 Year Ago12/22/22 to 12/22/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)1 Buy rating(s)2 Buy rating(s)Hold3 Hold rating(s)7 Hold rating(s)7 Hold rating(s)9 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$45.00$45.00$44.13$36.00Forecasted Upside0.09% Upside0.09% Upside-1.86% Downside-14.08% DownsideConsensus RatingHoldHoldHoldHold 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] CERE Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History CERE Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Cerevel Therapeutics Stock vs. The CompetitionTypeCerevel TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.00 2.81 2.51Consensus RatingHoldModerate BuyModerate BuyPredicted Upside0.09% Upside25,828.57% Upside14.53% UpsideNews Sentiment RatingNeutral NewsSee Recent CERE NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails2/16/2024Mizuho3 of 5 stars Boost TargetNeutral ➝ Neutral$25.00 ➝ $45.00+5.71%12/28/2023JPMorgan Chase & Co.3 of 5 stars Boost TargetNeutral ➝ Neutral$25.00 ➝ $45.00+6.38%12/22/2023Jefferies Financial Group2 of 5 stars Reiterated RatingBuy ➝ Hold$40.00 ➝ $45.00+8.72%12/8/2023TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Market Perform$45.00+9.41%12/7/2023HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. TsaoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$41.00 ➝ $45.00+9.78%12/7/2023Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingC. DuncanSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$38.00 ➝ $45.00+21.85%12/7/2023Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOverweight ➝ Neutral$33.00 ➝ $45.00+21.85%11/2/2023Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight ➝ Overweight$42.00 ➝ $38.00+52.73%8/3/2023Bank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Neutral$36.00 ➝ $31.00+17.74%5/4/2023Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy rating UpgradeEqual Weight ➝ Overweight$30.00-6.02%3/16/2023Berenberg BankSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageHold$22.00-10.02%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:38 PM ET. CERE Forecast - Frequently Asked Questions What is Cerevel Therapeutics' forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Cerevel Therapeutics is $45.00, with a high forecast of $45.00 and a low forecast of $45.00. Should I buy or sell Cerevel Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CERE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CERE, but not buy additional shares or sell existing shares. Does Cerevel Therapeutics's stock price have much upside? According to analysts, Cerevel Therapeutics's stock has a predicted upside of 0.09% based on their 12-month stock forecasts. Do Wall Street analysts like Cerevel Therapeutics more than its competitors? Analysts like Cerevel Therapeutics less than other "medical" companies. The consensus rating for Cerevel Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CERE compares to other companies. Stock Forecasts and Research Tools Related Companies CNX Resources Stock Forecast Warrior Met Coal Stock Forecast Arch Resources Stock Forecast Hallador Energy Stock Forecast Alnylam Pharmaceuticals Stock Forecast Teva Pharmaceutical Industries Stock Forecast BeiGene Stock Forecast United Therapeutics Stock Forecast Viatris Stock Forecast Royalty Pharma Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] This page (NASDAQ:CERE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
